Roger Adsett - 08 Mar 2022 Form 4 Insider Report for Landos Biopharma, Inc.

Role
Director
Signature
/s/ Eric W. Blanchard, attorney-in-fact
Issuer symbol
N/A
Transactions as of
08 Mar 2022
Net transactions value
$0
Form type
4
Filing time
10 Mar 2022, 15:19:41 UTC
Previous filing
13 Jan 2022
Next filing
13 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Stock Option (right to buy) Award $0 +36,000 $0.000000 36,000 08 Mar 2022 Common Stock 36,000 $1.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock underlying this option will vest and become exercisable in 36 equal monthly installments beginning on March 8, 2022, subject to the Reporting Person's continuous service with the Issuer on each such date.